Sallustio B C, Harkin L A, Mann M C, Krivickas S J, Burcham P C
Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville, South Australia.
Toxicol Appl Pharmacol. 1997 Dec;147(2):459-64. doi: 10.1006/taap.1997.8322.
Glucuronides formed from carboxylate-containing xenobiotics are more chemically reactive than most Phase II conjugates. However, while they have been shown to form protein adducts, their reactions with DNA have received little attention. We thus used the M13 forward mutational assay to assess the genotoxicity of acyl glucuronides formed from two widely used fibrate hypolipidemics, clofibric acid and gemfibrozil. Single-stranded M13mp19 bacteriophage DNA was incubated in pH 7.4 buffer for 16 h in the presence of 0, 1, 2.5, and 5 mM concentrations of each glucuronide as well as the respective aglycones. The modified DNA was then transfected into SOS-induced competent Escherichia coli JM105 cells and the transfection efficiency was determined after phage growth overnight at 37 degrees C. Significantly, both acyl glucuronides, but not the aglycones, caused a concentration-dependent decrease in the transfection efficiency of the DNA, with a greater than 80% decrease in phage survival produced by the 5 mM concentrations of the glucuronides. No increase in lacZa mutations accompanied the loss of phage survival. We propose that these genotoxic effects involve reactions with nucleophilic centers in DNA via a Schiff base mechanism that is analogous to the glycosylation of DNA by endogenous sugars. Since strand nicking is known to accompany such damage, we also analyzed glucuronide-treated pSP189 plasmids for strand breakages via agarose gel electrophoresis. Both clofibric acid and gemfibrozil glucuronides produced significant concentration-related strand nicking and exhibited over 10-fold greater reactivity than the endogenous glycosylating agent, glucose 6-phosphate. On the basis of these findings, the possibility that this novel bioactivation route participates in the carcinogenicity of the fibrate hypolipidemics deserves investigation.
由含羧基的外源生物活性物质形成的葡糖醛酸苷比大多数II相缀合物的化学反应性更强。然而,虽然已证明它们能形成蛋白质加合物,但它们与DNA的反应却很少受到关注。因此,我们使用M13正向突变试验来评估由两种广泛使用的贝特类降血脂药(氯贝酸和吉非贝齐)形成的酰基葡糖醛酸苷的遗传毒性。将单链M13mp19噬菌体DNA在pH 7.4缓冲液中,于0、1、2.5和5 mM浓度的每种葡糖醛酸苷以及各自的苷元存在下孵育16小时。然后将修饰后的DNA转染到经SOS诱导的感受态大肠杆菌JM105细胞中,并在37℃下噬菌体生长过夜后测定转染效率。值得注意的是,两种酰基葡糖醛酸苷,而非苷元,导致DNA转染效率呈浓度依赖性下降,5 mM浓度的葡糖醛酸苷使噬菌体存活率下降超过80%。噬菌体存活率的丧失并未伴随lacZa突变的增加。我们认为这些遗传毒性作用涉及通过席夫碱机制与DNA中的亲核中心发生反应,这类似于内源性糖类对DNA的糖基化作用。由于已知这种损伤会伴随链切口的出现,我们还通过琼脂糖凝胶电泳分析了经葡糖醛酸苷处理的pSP189质粒的链断裂情况。氯贝酸和吉非贝齐葡糖醛酸苷均产生了显著的浓度相关链切口,并且其反应活性比内源性糖基化剂6-磷酸葡萄糖高10倍以上。基于这些发现,这种新的生物活化途径参与贝特类降血脂药致癌性的可能性值得研究。